This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Best Biotech CEO of 2012 Is...

BOSTON ( TheStreet) -- The best biotech CEO of 2012 is Leonard Schleifer of Regeneron Pharmaceuticals (REGN - Get Report).

Schleifer was the top pick of TheStreet readers for his execution of one of the most successful new drug launches in history. Eylea was approved in November 2011 to treat a common cause of blindness. In just nine months, Eylea sales have already reached $562 million with an annual run rate close to $1 billion, well above the company's -- and investors' -- initial forecasts.

Well done, Len!

Schleifer wins the 2012 Best Biotech CEO Award with 37% of 1,121 votes cast. For his victory, Schleifer takes home the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO.

The runner-up this year was Onyx Pharmaceuticals' (ONXX) Tony Coles with 28% of votes cast. With two new cancer drug approvals in 2012, Coles had a stellar year.

Right behind Coles in third place, just six votes short, was Chris Garabedian of Sarepta Therapeutics (SRPT - Get Report). In fourth place: Gilead Sciences' (GILD - Get Report) John Martin.

Congratulation to all of this year's Best Biotech CEO nominees, and thanks to everyone who participated in the voting process.

-- Reported by Adam Feuerstein in Boston.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
GILD $103.69 0.73%
REGN $465.60 -1.70%
SRPT $13.06 -1.10%
AAPL $130.30 -1.80%

Markets

DOW 18,091.32 +53.35 0.30%
S&P 500 2,114.48 +5.56 0.26%
NASDAQ 5,055.8560 -4.39 -0.09%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs